Works by Seigo Kinuya

Results: 217
    1
    2
    3
    4
    5

    Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine.

    Published in:
    Journal of Nuclear Medicine, 2023, v. 64, n. 6, p. 986, doi. 10.2967/jnumed.123.265603
    By:
    • Urbain, Jean-Luc;
    • Scott, Andrew M.;
    • Sze Ting Lee;
    • Buscombe, John;
    • Weston, Charlotte;
    • Jun Hatazawa;
    • Seigo Kinuya;
    • Singh, Baljinder;
    • Haidar, Mohamad;
    • Ross, Andrew;
    • Lamoureux, Francois;
    • Kunikowska, Jolanta;
    • Wadsak, Wolfgang;
    • Dierckx, Rudi;
    • Paez, Diana;
    • Giammarile, Francesco;
    • Kyung-Han Lee;
    • Joo Hyun O;
    • Moshe, Modiselle;
    • Louw, Lizette
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    編集後記.

    Published in:
    Japanese Journal of Nuclear Medicine / Kaku Igaku, 2014, v. 51, n. 4, p. 526
    By:
    • Kinuya Seigō
    Publication type:
    Article
    23
    24
    25

    編集後記.

    Published in:
    Japanese Journal of Nuclear Medicine / Kaku Igaku, 2013, v. 50, n. 2, p. 103
    By:
    • Kinuya Seigo
    Publication type:
    Article
    26
    27
    28
    29
    30

    Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 4, p. 745, doi. 10.1007/s00280-009-1219-y
    By:
    • Yagi, Yasumichi;
    • Fushida, Sachio;
    • Harada, Shinichi;
    • Tsukada, Tomoya;
    • Kinoshita, Jun;
    • Oyama, Katsunobu;
    • Fujita, Hideto;
    • Ninomiya, Itasu;
    • Fujimura, Takashi;
    • Kayahara, Masato;
    • Kinuya, Seigo;
    • Yashiro, Masakazu;
    • Hirakawa, Kousei;
    • Ohta, Tetsuo
    Publication type:
    Article
    31

    Safety and response after peptide receptor radionuclide therapy with <sup>177</sup>Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.

    Published in:
    Journal of Hepato -- Biliary -- Pancreatic Sciences, 2022, v. 29, n. 4, p. 487, doi. 10.1002/jhbp.1101
    By:
    • Kudo, Atsushi;
    • Tateishi, Ukihide;
    • Yoshimura, Ryoichi;
    • Tsuchiya, Junichi;
    • Yokoyama, Kota;
    • Takano, Shoko;
    • Kobayashi, Noritoshi;
    • Utsunomiya, Daisuke;
    • Hata, Masaharu;
    • Ichikawa, Yasushi;
    • Tanabe, Minoru;
    • Hosono, Makoto;
    • Kinuya, Seigo
    Publication type:
    Article
    32
    33
    34
    35
    36

    A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.

    Published in:
    International Journal of Clinical Oncology, 2020, v. 25, n. 4, p. 720, doi. 10.1007/s10147-019-01589-6
    By:
    • Matsubara, Nobuaki;
    • Kimura, Go;
    • Uemura, Hiroji;
    • Uemura, Hirotsugu;
    • Nakamura, Motonobu;
    • Nagamori, Satoshi;
    • Mizokami, Atsushi;
    • Kikukawa, Hiroaki;
    • Hosono, Makoto;
    • Kinuya, Seigo;
    • Krissel, Heiko;
    • Siegel, Jonathan;
    • Kakehi, Yoshiyuki
    Publication type:
    Article
    37

    Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

    Published in:
    International Journal of Clinical Oncology, 2019, v. 24, n. 5, p. 557, doi. 10.1007/s10147-018-01389-4
    By:
    • Uemura, Hirotsugu;
    • Uemura, Hiroji;
    • Nagamori, Satsohi;
    • Wakumoto, Yoshiaki;
    • Kimura, Go;
    • Kikukawa, Hiroaki;
    • Yokomizo, Akira;
    • Mizokami, Atsushi;
    • Kosaka, Takeo;
    • Masumori, Naoya;
    • Kawasaki, Yoshihide;
    • Yonese, Junji;
    • Nasu, Yasutomo;
    • Fukasawa, Satoshi;
    • Sugiyama, Takayuki;
    • Kinuya, Seigo;
    • Hosono, Makoto;
    • Yamaguchi, Iku;
    • Akagawa, Takashi;
    • Matsubara, Nobuaki
    Publication type:
    Article
    38

    Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

    Published in:
    International Journal of Clinical Oncology, 2018, v. 23, n. 1, p. 173, doi. 10.1007/s10147-017-1176-0
    By:
    • Nobuaki Matsubara;
    • Satsohi Nagamori;
    • Yoshiaki Wakumoto;
    • Hirotsugu Uemura;
    • Go Kimura;
    • Akira Yokomizo;
    • Hiroaki Kikukawa;
    • Atsushi Mizokami;
    • Takeo Kosaka;
    • Naoya Masumori;
    • Yoshihide Kawasaki;
    • Junji Yonese;
    • Yasutomo Nasu;
    • Satoshi Fukasawa;
    • Takayuki Sugiyama;
    • Seigo Kinuya;
    • Makoto Hosono;
    • Iku Yamaguchi;
    • Hirokazu Tsutsui;
    • Hiroji Uemura
    Publication type:
    Article
    39
    40
    41
    42

    Phase I/II clinical trial of high-dose [<sup>131</sup>I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 5, p. 1574, doi. 10.1007/s00259-021-05630-7
    By:
    • Kuroda, Rie;
    • Wakabayashi, Hiroshi;
    • Araki, Raita;
    • Inaki, Anri;
    • Nishimura, Ryosei;
    • Ikawa, Yasuhiro;
    • Yoshimura, Kenichi;
    • Murayama, Toshinori;
    • Imai, Yasuhito;
    • Funasaka, Tatsuyoshi;
    • Wada, Taizo;
    • Kinuya, Seigo
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50